Corvus Pharmaceuticals, Inc. (CRVS)

1.4100 +0.0500 (+3.68%) At close: 04:00PM EDT

Corvus Pharmaceuticals, Inc.

863 Mitten Road
Suite 102
Burlingame, CA 94010
United States
650 900 4520
https://www.corvuspharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 28

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Richard A. Miller M.D.	Co-Founder, President, CEO & Chairman of the Board	306k	N/A	1951
Dr. Peter A. Thompson FACP, M.D.	Co-Founder & Independent Director	47k	N/A	1960
Mr. Leiv Lea	Chief Financial Officer	388.73k	N/A	1954
Dr. William Benton Jones Ph.D.	Senior Vice President of Pharmaceutical Development	346.42k	N/A	1966
Dr. James T. Rosenbaum M.D.	Senior Vice President of Research	N/A	N/A	N/A
Mr. Jeffrey S. Arcara	Chief Business Officer	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Corporate governance

Corvus Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.